Overview of Vedafil

Quick Facts: Vedafil

Property	Description
Active ingredient	Sildenafil (as the Citrate salt)
Form	Oral Tablets (Film-coated Tablets)
Pharmacological class	PDE5 Inhibitor
General purpose	Facilitates localized blood flow
Origin	Synthetic compound (pyrazolopyrimidinone derivative)

What Type of Medicine is Vedafil? (Identity and Classification)

Vedafil is a pharmaceutical product containing the active ingredient Sildenafil, a synthetic drug clinically recognized and classified as a highly selective Phosphodiesterase type 5 (PDE5) Inhibitor. This classification defines its specialized pharmacological role, focusing on enzyme inhibition. Unlike general vasodilators, PDE5 inhibitors are chemically distinguished by their mechanism, targeting the PDE5 enzyme concentrated in specific vascular smooth muscle tissues. The drug's designation as a Prescription-Only Medicine (POM) confirms its potency and requirement for medical oversight. Sildenafil is utilized to manage localized circulatory issues through the inhibition of the PDE5 enzyme.

Composition and Form of Vedafil (Ingredient and Presentation)

The therapeutic action of Vedafil is delivered by its single active ingredient, Sildenafil, which is commonly formulated as the Citrate salt, making it a single-component product. This medication is typically supplied for Systemic Oral administration in the form of Film-coated Tablets. The compound's structure as a pyrazolopyrimidinone derivative confers its specific inhibitory activity. The solid oral tablet form ensures reliable systemic bioavailability, allowing the drug to be absorbed into the bloodstream. This formulation provides a convenient and precisely measured dose of the compound.

What is the General Purpose of Sildenafil? (Therapeutic Rationale)

The general purpose of Sildenafil is to facilitate localized blood vessel relaxation leading to increased local blood flow. The drug achieves this by selectively inhibiting the PDE5 enzyme, an action that enhances a natural cellular signal known as cGMP (cyclic Guanosine Monophosphate). By protecting the cGMP signal from breakdown, Sildenafil encourages the smooth muscles in targeted blood vessels to widen. This improved blood flow dynamic provides the necessary physiological foundation for managing conditions related to inadequate circulatory support in specific organ systems.

Regulatory References

MedlinePlus Sildenafil Profile

What side effects are possible with Vedafil?

Possible side effects and safety information

The safety profile of Vedafil, which contains Sildenafil, is characterized by adverse reactions that are classified based on their officially reported frequency in regulatory documentation. These reactions are grouped according to the System-Organ-Classes (SOC) affected.

Frequency-Classified Adverse Reactions

Classification	Example Adverse Reaction	System-Organ Class
Very Common (ge 1/10)	Headache	Nervous System Disorders
Common (ge 1/100 to < 1/10)	Flushing, Dyspepsia, Visual disturbances, Nasal congestion	Vascular, Gastrointestinal, Eye, Respiratory
Uncommon (ge 1/1,000 to < 1/100)	Hypotension, Tachycardia, Nausea, Rash	Vascular, Cardiac, Gastrointestinal, Skin

Serious Adverse Reactions and Restrictions

The official label documents several serious adverse reactions, including Priapism (a prolonged erection lasting more than four hours) and reports of Non-arteritic Anterior Ischemic Optic Neuropathy (NAION), a cause of sudden vision loss. Serious cardiovascular events, such as myocardial infarction and stroke, have also been reported in temporal association with its use.

Regulatory documents impose a fundamental absolute restriction against the co-administration of Sildenafil with any form of nitrate drug therapy or nitric oxide donors, due to the potential for severe, life-threatening hypotension.

Population-Specific Safety Notes

Safety statements include specific considerations for certain patient groups. Individuals classified as older adults (ages ge 65) and patients with severe hepatic (liver) or renal (kidney) impairment may require careful initial safety consideration, as their bodies may process the drug differently. Furthermore, certain adverse reactions, such as headache and flushing, are often reported more frequently during the initial phases of treatment.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents define overdose of Vedafil (Sildenafil) as resulting in an exaggeration of the drug's known adverse effects. These presentations can include an increased incidence of headache, flushing, dizziness, dyspepsia, and decreased blood pressure (hypotension).

Time-Critical Emergency Actions

The following conditions require immediate action as stated in the prescribing information:

Condition	Required Action (Regulatory Mandate)
Prolonged erection (lasting more than 4 hours)	Seek immediate medical assistance to prevent permanent penile tissue damage and loss of potency.
Sudden loss of vision or hearing	Seek immediate medical attention for sudden decrease or loss of either sense.

Officially Documented Management

There is no specific antidote listed for Sildenafil overdose. Management is based on the severity of the symptoms observed. Official guidance requires that symptomatic treatment and standard supportive measures be instituted by medical professionals. Due to the way Sildenafil is processed by the body, specific procedures like renal dialysis are not expected to accelerate clearance.

Regulatory warnings also note that in a study of pediatric patients with Pulmonary Arterial Hypertension (PAH), increased mortality was observed with increasing doses.

Therapeutic Uses of Vedafil

What Vedafil Treats: Main Uses and Benefits

This medication is used to address two primary and distinct therapeutic domains. It is generally applied across domains where additional symptomatic support is needed to address increased discomfort or tension.

“The primary goal is to provide supportive relief that helps patients cope more steadily with symptom fluctuations in both vascular-related functional impairment and chronic cardiopulmonary stress.”

Support for Impaired Erectile Function

Vedafil is commonly used to help manage the symptom of erectile dysfunction, a condition characterized by periods of heightened symptoms related to functional sexual response. This application is relevant in conditions presenting with symptoms that create noticeable functional strain. The primary benefit is that it provides support that helps ease the overall symptom burden, which may assist with maintaining functional stability.

Quick Fact: Relief for Functional Strain

Area	Symptom Focus	Therapeutic Benefit
Sexual Health	Inability to sustain erection	Supports functional stability for sexual activity
Cardiopulmonary	Reduced exercise tolerance	Contributes to improved comfort during symptomatic periods

Management of Pulmonary Arterial Hypertension (PAH)

The medication is also considered relevant in the therapeutic area of Pulmonary Arterial Hypertension (PAH), conditions marked by increased physiological stress within the pulmonary system. It is applied in clinical settings that involve acute or unstable symptom patterns, such as reduced exercise tolerance and shortness of breath. This use is applied in addressing symptoms linked to organ-specific functional stress, which contributes to improved comfort during symptomatic periods and supports patients during difficult episodes by easing distress and assists with maintaining functional stability.

Regulatory References

NIH MedlinePlus overview on Sildenafil

Eligibility and Restrictions for Use

Vedafil (Sildenafil) eligibility is strictly defined by government regulatory agencies based on age, existing health conditions, and use of certain concomitant medications.

Populations for Whom Use is Contraindicated

The use of Vedafil is contraindicated (absolutely forbidden) in individuals concurrently using organic nitrates/nitric oxide donors (in any form) or the drug riociguat. Contraindication also applies to patients with a history of non-arteritic anterior ischaemic optic neuropathy (NAION), known hypersensitivity to Sildenafil, and those with severe hepatic impairment.

Age- and Condition-Related Limitations

Classification	Eligibility Rule (Official Labeling)
Age-Group Eligibility	Not indicated for Erectile Dysfunction use in those under 18 years; a lower starting dose is recommended for older adults ( ge 65 years).
Pregnancy/Lactation Status	The medicine is not indicated for women for the ED use; use in pregnancy and lactation is characterized by a lack of adequate and well-controlled studies.
High-Risk Comorbidities	Contraindicated in patients with severe cardiovascular events (e.g., recent stroke or myocardial infarction within six months) or resting hypotension ( BP <90/50 mmHg).
Organ Function Restriction	A lower starting dose is recommended for patients with severe renal impairment (CLcr <30 mL/min).

Official regulatory documents define a narrow eligibility scope, excluding patients based on these severe cardiovascular, hepatic, and medication-interaction risks. Use in pediatric patients for the PAH indication carries a major official caution against chronic use.

What should I know about interactions with other medicines?

Vedafil (Sildenafil) interactions are formally documented by regulatory authorities, focusing on specific pharmacokinetic changes and additive pharmacodynamic effects. All statements below reflect officially documented interaction patterns and regulatory restrictions.

Contraindicated and Restricted Combinations

Combination	Interaction Classification	Official Restriction
Organic Nitrates (all forms)	Pharmacodynamic	Strictly contraindicated due to severe, additive hypotensive risk.
Riociguat (Guanylate Cyclase Stimulator)	Pharmacodynamic	Contraindicated due to potential for potentiating hypotensive effects.
Other PDE5 Inhibitors	Avoided combination	Official regulatory guidance advises to avoid use.

Exposure-Altering and Timing Restrictions

The most significant pharmacokinetic interaction involves the Cytochrome P450 3A4 (CYP3A4) enzyme, which metabolizes Sildenafil. Strong CYP3A4 Inhibitors (e.g., Ritonavir, Ketoconazole) reduce Sildenafil clearance, leading to a marked increase in plasma exposure. For example, co-administration with Ritonavir mandates a restriction that the dose must not exceed 25 mg within a 48-hour period.

Pharmacodynamic effects include an officially documented additive blood pressure-lowering effect with Alpha-blockers and other antihypertensive agents, which carries a risk of symptomatic hypotension. The interaction with a high-fat meal is documented to slow the rate of absorption and delay the time to peak concentration. Clearance is also reduced in patients with Hepatic Impairment, a population-specific note that increases overall exposure.

Mechanism of Action

How Vedafil Works

Selective Enzyme Inhibition

Vedafil exerts its action by functioning as a highly selective inhibitor of the enzyme Phosphodiesterase type 5 (PDE5), which is concentrated in the smooth muscle cells of specific blood vessels. This molecular interaction prevents the hydrolysis of the cGMP signal, thereby blocking the enzyme's ability to degrade this critical intracellular messenger.

Enhancement of the cGMP Pathway

The drug's mechanism is to enhance the body’s natural Nitric Oxide (NO) / cGMP signaling pathway. Vedafil does not initiate the process; instead, it prolongs and amplifies the duration of the cGMP signal that is naturally generated following physiological stimulation. This action ensures that the signaling cascade persists longer within the cells.

Modulation of Vascular Smooth Muscle Tone

The sustained cGMP levels lead to a modulation of vascular smooth muscle tone, causing the muscle cells in the artery walls to relax. This ultimately results in localized vasodilation (blood vessel widening), which leads to increased localized blood flow to the targeted region. This adjustment defines the systemic consequence of the mechanism.

Dosage and Administration Information

The administration of Vedafil (Sildenafil) is characterized by distinct usage patterns that depend on the approved indication. The medication is primarily for Oral administration in the form of film-coated tablets, but an Intravenous (IV) form is also available, typically used as a temporary substitute for oral dosing in Pulmonary Arterial Hypertension (PAH).

Intermittent Use: Erectile Dysfunction

The regimen for Erectile Dysfunction (ED) is intermittent and as needed. The usual starting oral dose is 50 mg, with the allowed dose range being 25 mg to 100 mg. Administration is restricted to a maximum frequency of once per day. The dose is generally taken between 30 minutes and 4 hours prior to anticipated activity. Taking the dose with food may delay its absorption and the time to onset of activity.

Continuous Use: Pulmonary Arterial Hypertension

For PAH, the drug follows a continuous, scheduled regimen. The standard adult oral dosing range is 20 mg to 80 mg, administered three times daily (TID), with doses separated by approximately four to six hours. The specific 20 mg tablets are prescribed for this regimen; the larger ED tablet strengths are not intended for use in the continuous PAH protocol.

Population-Specific Adjustments

A lower initial dose of 25 mg is considered for older adults (aged 65 years and older) and patients with severe renal or hepatic impairment due to established pharmacokinetic factors. Dosing for pediatric patients with PAH is determined based on body weight, with specific dose tables available.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Vedafil

Evidence for Use in Impaired Erectile Function

The research exploring whether Vedafil affects symptoms of erectile dysfunction (ED) was primarily based on numerous short-term randomized controlled trials (RCTs). These studies were structured to compare the medication against a placebo in a double-blind manner. These trials were used in research exploring how symptoms change over time and focus on functional outcomes reflecting daily functioning or activity level.

In these studies, researchers examined whether the medication was associated with changes in the ability to attain and maintain an erection suitable for sexual intercourse. The findings describe patterns observed in the studies, particularly concerning patient-reported outcomes describing perceived discomfort and functional stability. Research provides insight into short-term changes and helps contextualize how patients reported their experience during periods of increased symptom activity.

The body of research for this use includes numerous short-term randomized trials, but it is important to note where research gaps and limitations exist. The core functional findings rely heavily on the results of short-term trials, typically lasting only a few weeks. Although follow-up data from open-label extensions suggest that these initial functional responses may be maintained over a longer period, limited information is available for long-term outcomes in controlled settings.

Evidence for Use in Pulmonary Arterial Hypertension (PAH)

Research for Vedafil was studied for use in managing pulmonary arterial hypertension (PAH) and has relied on key randomized controlled trials (RCTs) that monitored patient responses over a defined time interval, typically 12 to 16 weeks. PAH is one of the conditions marked by functional limitations and involves physiological strain or stress in the lungs.

The studies monitored outcomes reflecting daily functioning or activity level, such as the 6-Minute Walk Distance (6MWD), which is a measure of exercise capacity. Researchers also studied the impact on a composite endpoint called time to clinical worsening, which tracks events like hospitalization or mortality. Findings describe patterns observed in the studies, where time to clinical worsening was associated with the medication in some trials. Additionally, studies monitored hemodynamic parameters, which are measurements of blood pressure and flow within the pulmonary arteries.

Research Gaps and Areas of Uncertainty

A key limitation is the lack of extensive, controlled long-term data for adults in both indications. While open-label extensions exist, they cannot provide the same level of certainty regarding long-term outcomes as controlled trials. Comparative evidence is lacking; there is limited information directly comparing Vedafil to other similar or alternative treatments in head-to-head clinical trials. For the pediatric PAH population, the data from one large, long-term extension study later reported specific areas of concern in clinical outcomes, indicating that subgroup findings are uncertain and data are still emerging.

Key Studies & References

Sildenafil (Viagra): MedlinePlus Drug Information (NIH)

Frequently Asked Questions (FAQ)

Common questions about Vedafil (FAQ)

Q: Is Vedafil the same kind of medicine as other well-known treatments in the same area?

A: This medicine is classified as a Phosphodiesterase type 5 (PDE5) inhibitor, and it was the first compound developed in this particular drug class. This classification means it works through a specific, selective mechanism of action that defines it as a distinct treatment for its approved conditions.

Q: Is it true that Vedafil has been studied for any other conditions besides its main use?

A: Research has investigated the medicine’s potential use for conditions other than its approved indications, such as Raynaud’s phenomenon and high-altitude pulmonary edema (HAPE). However, official regulatory bodies have not approved the use of this medicine for these other conditions.

Q: Is it only men who are eligible to use Vedafil, or can women also use it?

A: Official prescribing information confirms that the medicine is used to treat Pulmonary Arterial Hypertension (PAH) in both men and women. However, it is important to note that the medicine is not indicated for women for the treatment of Erectile Dysfunction.

Q: What happens in the body when Vedafil is at its peak concentration?

A: The concentration of the active ingredient typically reaches its maximum level in the blood about one hour after the tablet is taken. This concentration peak corresponds to the period when the pharmacological action is generally at its highest.

Q: Does Vedafil's effectiveness change for older versus younger adults?

A: Official dosing instructions recommend that a lower starting dose be considered for older adults, generally those age 65 and over. This adjustment is due to age-related changes in the body's ability to clear the medicine, which is why regulatory recommendations specify that a lower dose should be considered for this population to achieve comparable drug exposure.

Q: Does Vedafil stay in the system for a long time?

A: The time the active ingredient stays in the system is described by its half-life, which is approximately four hours. Official pharmacokinetic data indicates that the active ingredient is typically mostly cleared from the body's plasma within approximately 16 to 20 hours.

Q: What does official guidance say about using Vedafil and alcohol consumption?

A: Official patient information advises caution regarding the use of this medicine with alcohol. Alcohol consumption may increase the risk of side effects such as fainting or dizziness, as both substances can contribute to lowering blood pressure.

Q: What should be expected regarding the duration of Vedafil's effects?

A: The duration of the medicine’s intended effects is closely related to its half-life, meaning the pharmacological action typically lasts for around four hours. While the intended effect is often associated with this duration, a satisfactory response has been observed for a longer period in some instances.

Q: Can taking Vedafil cause feelings of dizziness or lightheadedness?

A: According to regulatory safety documents, dizziness and lightheadedness are reported as common side effects of the medicine. These are often linked to the drug’s vasodilatory, or blood vessel widening, properties.

Q: Is there anything mentioned in official warnings about using Vedafil with grape juice?

A: Official warnings indicate that consuming grapefruit juice may interfere with the body’s normal process for breaking down the medicine. This interaction could lead to an increased concentration of the active ingredient in the bloodstream, potentially raising the risk of side effects.

Q: What happens if a person misses a time they were supposed to use Vedafil?

A: Official patient guidance related to the continuous daily-dosing regimen (PAH) provides principles for managing a missed intake. These principles describe the circumstances under which a dose should be taken immediately and when it should be omitted to avoid taking multiple doses close together.

Q: What does the research say about the consistency of Vedafil's results?

A: Regulatory clinical trials report high efficacy rates for both approved indications. For Erectile Dysfunction, clinical trials demonstrate that a large majority of participants experienced improved functional outcomes. For Pulmonary Arterial Hypertension, data showed significant improvement in exercise capacity.

Q: Do official patient information leaflets mention anything about Vedafil and driving/operating machinery?

A: Official patient information indicates that, due to the risk of side effects such as dizziness and changes in vision, caution should be exercised regarding activities like driving or operating machinery.

Q: Is there a mention in safety data about Vedafil affecting hearing?

A: Official safety data documents that a sudden decrease or loss of hearing is a rare but serious adverse event. Official safety information emphasizes that if a patient experiences this rare event, immediate medical assessment is required.

Q: Does official literature indicate that Vedafil is less effective over time?

A: Regulatory-aligned clinical reviews suggest that the body does not appear to develop pharmacological tolerance to the medicine itself. However, the perceived effectiveness of the treatment can vary over time due to changes in a patient's underlying health status or condition.

Q: Can Vedafil be taken with other medicines that treat high cholesterol?

A: Official drug interaction data does not list a major interaction with common cholesterol-lowering medicines (statins). Furthermore, some research has explored the use of the medicine in combination with statins for treating Pulmonary Arterial Hypertension.

Q: Does Vedafil have any interactions with herbal products like St. John's Wort?

A: Co-administration with the herbal product St. John's Wort may affect the medicine’s concentration in the body. This interaction may reduce the blood levels and intended effects of the medicine by speeding up the rate at which the body breaks it down.

Q: Can Vedafil interact with common pain relievers like ibuprofen or acetaminophen?

A: Official drug interaction data does not currently list a known significant drug interaction between this medicine and common over-the-counter pain relievers such as ibuprofen or acetaminophen.

Q: What is the official definition of the condition Vedafil treats?

A: This medicine, containing Sildenafil, is classified as a phosphodiesterase type 5 (PDE5) inhibitor. It is approved by regulatory bodies for treating Erectile Dysfunction and Pulmonary Arterial Hypertension (PAH), where its action works by relaxing blood vessels to facilitate localized blood flow.

How should Vedafil be stored and disposed of?

Storage and Disposal Requirements

Vedafil (sildenafil) must be stored according to official regulatory guidelines to maintain stability and effectiveness.

Storage Conditions

Requirement	Official Instruction
Temperature	Store at controlled room temperature, 20 C to 25 C (68 F to 77 F), with excursions up to 30 C (86 F).
Protection	Keep in the original, tightly closed container to protect from moisture. Do not store in high-humidity areas like a bathroom.
Child Safety	Keep out of the reach of children.

Disposal Instructions

Expired or unused tablets should not be flushed down a toilet or sink. The preferred method for disposal is to use an authorized drug take-back program. If a take-back program is not available, unused medicine should be mixed with an undesirable substance (e.g., used coffee grounds) and placed in a sealed bag before being thrown in the household trash, in accordance with local regulations.

Vedafil